-
As Canada takes on US tariffs, what's behind the David and Goliath fight?
-
Veteran promoter Warren says it's Joshua's job to agree Fury fight
-
UEFA 'likely' to drop threat to boycott FIFA tournaments: source
-
Ex-champ Wawrinka gets last-minute wildcard to US Open
-
US disrupts platforms allegedly used by Chinese hackers
-
Brennan blasts to Vuelta stage five victory, Pogacar holds lead
-
The foreign tourists missing in Nepal's flash floods
-
What could change for US teens on Instagram and Facebook
-
Hundreds missing after Nepal-Tibet flood kills 98
-
Meta, US states agree $16.7 bn settlement in landmark teen safety case
-
CIA director was on 'semi-routine' mission in Moscow: Trump
-
'Point of no return' if Israel-Hamas truce fails: US envoy to Gaza board
-
Aldeguer switches to Rossi's VR46 for next season
-
Barcelona holding out hope for Alvarez as Atletico resist sale
-
Rent TRON Energy and Reduce USDT Fees : TronBid Expands Marketplace
-
Werro basks in new status, shelves world record talk
-
Pakistan captain Babar Azam returns against England '90 percent fit'
-
Bill Gates warns world unprepared for AI upheaval
-
Stocks mixed as oil drops, inflation stays high
-
Prince Harry and family arrive back in Britain: UK media
-
Improving standards transform pole vault as spectacle, says Duplantis
-
German plan for sugar tax on Coke Zero fizzles out
-
India close in on win despite Sri Lanka fightback in second Test
-
Deadly flood hits Nepal-Tibet border, hundreds unaccounted for
-
MEXC TradFi Gala Concludes With Over 170,000 Registrations and $4.3 Billion in Daily Trading Volume
-
Tongue says Root has left England in no doubt over conduct standards
-
Olympic skating champion Liu to skip new season
-
Flags lowered across US for country music legend Dolly Parton
-
Benfica sign midfielder Palhinha from Bayern
-
Stocks gain as oil drops on Mideast hopes
-
Flick says Barca may go without striker as Atletico resist Alvarez sale
-
Bouaddi joins Man City for Premier League teenage record £85.6 mn
-
Too hot to incubate: Nile crocodiles hatch on their own in French reserve
-
Reclusive Hungarian author Peter Nadas dies aged 83
-
Spurs closing in on Man City's Marmoush after signing Savio
-
Man City sign Lille's Bouaddi for 100 mn euros
-
Celtic count the cost of Champions League flop
-
Sooriyabandara, Mendis lead Sri Lanka fightback after follow-on
-
Lebanon accuses Israel of burning forest, farmland in south
-
With ropes and chants, thousands move Japanese castle
-
Nepal floods at China border kill 8, cause 'major casualties' in Tibet
-
Zurich Diamond League: five events to watch
-
France eases cow diets as cheesemakers sweat
-
'Black smoke' chokes Pakistan maternity ward as hospital fire kills 14 infants
-
America unites in mourning for Dolly Parton
-
French flight attendant wins landmark breast cancer ruling
-
Meta and US states discuss settlement in landmark social media trial: report
-
Sri Lanka 83-2 after India enforce follow-on in second Test
-
Fire haze threatens health of millions in Indonesia, ministry warns
-
LIGHTWAIT Exhibition Explores Vulnerability and Connection in London
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus.
Event: Q1 Investor Summit
Presentation Time: 11:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52091
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
Access Newswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESS Newswire
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Barinthus Biotherapeutics plc
View the original press release on ACCESS Newswire
R.Chavez--AT